Halozyme Therapeutics, Inc. (HALO) - What Are Researchers Saying About This Stock?

Key Points

• Analysts remain broadly bullish: Halozyme has a “Moderate Buy” consensus, with 9 buy and 1 strong-buy ratings among 13 analysts. The average 12-month price target is $99.55, though several firms recently raised targets as high as $130.
• Strong quarterly performance: The company reported adjusted earnings of $2.28 per share versus the $1.79 consensus estimate, while revenue rose 47.7% year over year to $481 million. Management issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Institutional ownership is high, but insiders have been selling: Institutions own 97.79% of Halozyme’s shares, with several major investors recently establishing or expanding positions. Insiders sold 125,852 shares worth about $13.5 million over the past 90 days, including sales by the CEO and a director under pre-arranged trading plans.

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the thirteen research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $99.55.

HALO has been the topic of a number of analyst reports. Leerink Partners upgraded Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and upped their price target for the company from $83.00 to $110.00 in a research report on Friday, August 7th. TD Cowen lifted their price objective on Halozyme Therapeutics from $105.00 to $130.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. Citigroup restated a "market outperform" rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a "neutral" rating in a report on Thursday, October 8th. Finally, HC Wainwright increased their target price on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday, October 7th.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company's stock, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of the company's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the sale, the director directly owned 58,839 shares in the company, valued at $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock worth $13,538,046 over the last ninety days. Corporate insiders own 2.50% of the company's stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of large investors have recently bought and sold shares of HALO. Bank of America Corp DE bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth $214,504,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $196,540,000. Jupiter Topco LLC acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $105,570,000. Caisse de depot et placement du Quebec bought a new stake in Halozyme Therapeutics in the second quarter valued at about $83,940,000. Finally, Congress Asset Management Co. increased its holdings in Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company's stock valued at $251,890,000 after purchasing an additional 1,052,509 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Up 0.9%

Shares of HALO opened at $125.63 on Friday. The stock has a market cap of $14.26 billion, a price-to-earnings ratio of 37.50, a P/E/G ratio of 0.47 and a beta of 0.88. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics has a 12 month low of $61.22 and a 12 month high of $126.23. The company has a 50-day moving average price of $111.37 and a two-hundred day moving average price of $87.03.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company's quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts predict that Halozyme Therapeutics will post 8.31 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.